1. 2000
2. Cyhoeddwyd

   The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

   Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Ion 2000, Yn: Value in Health. 3, 5, t. 373

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

3. Cyhoeddwyd

   Pragmatic trials - design features and implications for clinical decision making

   Hughes, D., Urdahl, H., Hughes, D. A. & Freemantle, N., 1 Awst 2000.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

4. Cyhoeddwyd

   The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

   Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Tach 2000.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

5. 2001
6. Cyhoeddwyd

   A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.

   Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

7. Cyhoeddwyd

   Accounting for non-compliance in pharmacoeconomic evaluations.

   Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Ion 2001, Yn: Pharmacoeconomics. 19, 12, t. 1185-1197

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

8. Cyhoeddwyd

   Economic evaluations during early (Phase II) drug development: A role for clinical trial simulations.

   Hughes, D., Hughes, D. A. & Walley, T., 1 Ion 2001, Yn: Pharmacoeconomics. 19, 11, t. 1069-1077

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

9. Cyhoeddwyd

   Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.

   Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Ion 2001, 2001 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

10. Cyhoeddwyd

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies.

    Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

11. Cyhoeddwyd

    Impact of non-compliance on the cost-effectiveness of statin therapy

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Medi 2001, Yn: Value in Health. 4, 6, t. 489

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

12. Cyhoeddwyd

    Pharmacometric analysis of duration of drug action: implications for improved forgiveness to medication non-compliance

    Hughes, D., Hughes, D. A. & Walley, T., 1 Medi 2001.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

13. Cyhoeddwyd

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Hyd 2001.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

14. Cyhoeddwyd

    The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature.

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Hyd 2001, Yn: Health Economics. 10, 7, t. 601-615

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

15. Cyhoeddwyd

    Impact of non-compliance on the clinical and cost-effectiveness of statins

    Hughes, D. & Hughes, D. A., 1 Tach 2001.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

16. 2002
17. Cyhoeddwyd

    Impact of non-compliance on the therapeutic coverage of oxybutynin – comparison of once- and twice-daily oral formulations.

    Hughes, D. & Hughes, D. A., 1 Ion 2002, 2002 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

18. Cyhoeddwyd

    Impact of non-compliance on the therapeutic coverage of risperidone – comparison of long acting injectible with oral formulations.

    Hughes, D. & Hughes, D. A., 1 Ion 2002, 2002 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

19. Cyhoeddwyd

    From efficacy to cost-effectiveness: accounting for non-compliance in pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Mai 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

20. Cyhoeddwyd

    Economic impact of poor compliance with pharmaceuticals.

    Hughes, D. & Hughes, D. A., 1 Awst 2002, Yn: Expert Review of Pharmacoeconomics and Outcomes Research. 2, 4, t. 327-335

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

21. Cyhoeddwyd

    Accurate and practical dosing of African populations using a height, weight and age model designed for lapdap

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

22. Cyhoeddwyd

    Economic evaluation during early (phase II) trials

    Hughes, D. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

23. Cyhoeddwyd

    Impact of non-compliance on the cost-effectiveness of pharmaceuticals

    Hughes, D. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

24. Cyhoeddwyd

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

25. Cyhoeddwyd

    The population pharmacokinetics of lapdap

    Hughes, D., Ward, S., Simpson, J., Aarons, L., Szwandt, S. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

26. 2003
27. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Mai 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

28. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Meh 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

29. Cyhoeddwyd

    Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modelling.

    Hughes, D., Hughes, D. A. & Walley, T., 1 Gorff 2003, Yn: Clinical Pharmacology and Therapeutics. 74, 1, t. 1-8

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

30. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Medi 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

31. Cyhoeddwyd

    Modelling changes in first line antimalarial therapy

    Hughes, D. & Hughes, D. A., 1 Medi 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

32. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

33. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003, Yn: Value in Health. 6, 6, t. 749

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

34. Cyhoeddwyd

    Cost-utility analysis of on demand rabeprazole and esomeprazole for symptomatic gastro oesophageal reflux disease

    Hughes, D., Hughes, D. A. & Dubois, D., 1 Tach 2003, Yn: Value in Health. 6, 6, t. 613

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

35. Cyhoeddwyd

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

36. Cyhoeddwyd

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

37. Cyhoeddwyd

    Use of PK-PD modelling to predict the impact of non-compliance

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

38. Cyhoeddwyd

    Drug compliance and pharmaceconomics

    Hughes, D. & Hughes, D. A., 1 Rhag 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

39. 2004
40. Cyhoeddwyd

    Approaches to pharmacoeconomic analysis

    Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 101-126

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

41. Cyhoeddwyd

    Clinical Pharmacology: Special safety considerations in drug development and pharmacovigilance.

    Hughes, D., Atuah, K. N., Hughes, D. A. & Pirmohamed, M., 1 Ion 2004, Yn: Drug Safety. 27, 8, t. 535-554

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

42. Cyhoeddwyd

    Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.

    Hughes, D., Hughes, D. A. & Dubois, D., 1 Ion 2004, Yn: Pharmacoeconomics. 22, 16, t. 1047-1059

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

43. Cyhoeddwyd

    Internationalisation of cost-effectiveness model for on-demand use of proton pump inhibitors - Belgium.

    Hughes, D. & Hughes, D. A., 1 Ion 2004, 2004 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

44. Cyhoeddwyd

    Modelling in health economics

    Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 141-154

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

45. Cyhoeddwyd

    The future challenges

    Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 167-174

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

46. Cyhoeddwyd

    Pharmacoeconomics in Wales: functions of the all Wales medicines strategy group

    Hughes, D. & Hughes, D. A., 1 Ebr 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

47. Cyhoeddwyd

    Pharmacoeconomics of pharmacogenetic testing: azathioprine

    Hughes, D., McAllister, R. & Hughes, D. A., 1 Ebr 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

48. Cyhoeddwyd

    Patient compliance and persistence with prescribed medication: Measurement and health economic impact

    Hughes, D., Koncz, T., Hughes, D. A., Cleemput, I. & Annemans, L., 1 Mai 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

49. Cyhoeddwyd

    Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

    Hughes, D., Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K. & Pirmohamed, M., 1 Meh 2004, Yn: Pharmacogenetics. 14, 6, t. 335-342

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

50. Cyhoeddwyd

    Introduction to pharmaeconomics

    Hughes, D. & Hughes, D. A., 1 Gorff 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

51. Cyhoeddwyd

    Pharmacoeconomic models that incorporate non-compliance

    Hughes, D. & Hughes, D. A., 1 Gorff 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

52. Cyhoeddwyd

    Pharmacoeconomics appraisals by the all Wales medicines strategy group

    Hughes, D. & Hughes, D. A., 1 Gorff 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

53. Cyhoeddwyd

    The difference between effectiveness and efficacy of antimalarial drugs in Kenya.

    Hughes, D., Amin, A. A., Hughes, D. A., Marsh, V., Abuya, T. O., Kokwaro, G. O., Winstanley, P. A., Ochala, S. A. & Snow, R. W., 1 Medi 2004, Yn: Tropical Medicine and International Health. 9, 9, t. 967-974

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

54. Cyhoeddwyd

    Economic evaluation of on-demand maintenance therapy with proton pump inhibitors in patients with symptomatic gastroesophageal reflux disease - a Monte-Carlo analysis for Italy

    Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Hyd 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

55. Cyhoeddwyd

    A single centre open phase IV study to evaluate the safety and tolerability of chlorproguanil-dapsone when dosed by defined height bands

    Hughes, D., Makanga, M., Winstanley, P. & Hughes, D. A., 1 Tach 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

56. Cyhoeddwyd

    Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease

    Hughes, D. & Hughes, D. A., 1 Tach 2004, Yn: Value in Health. 7, 6, t. 753

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

57. Cyhoeddwyd

    From efficacy to effectiveness and cost-effectiveness: modelling possibilities

    Hughes, D. & Hughes, D. A., 1 Tach 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

58. Cyhoeddwyd

    HLA-B*5701 and abacavir hypersensitivity - Reply.

    Hughes, D., Hughes, D. A., Park, B. K. & Pirmohamed, M., 1 Tach 2004, Yn: Pharmacogenetics. 14, 11, t. 784

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

59. 2005
60. Cyhoeddwyd

    Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease.

    Hughes, D., Hughes, D. A., Bodger, K., Bytzer, P., De Herdt, D. & Dubois, D., 1 Ion 2005, Yn: Pharmacoeconomics. 23, 10, t. 1031-1041

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

61. Cyhoeddwyd

    Improving Outcomes in Children and Young People with Cancer: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Ion 2005, 2005 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

62. Cyhoeddwyd

    Internationalisation of cost-effectiveness model for on-demand use of proton pump inhibitors - Sweden.

    Hughes, D. & Hughes, D. A., 1 Ion 2005, 2005 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

63. Cyhoeddwyd

    Welsh Health Economics Network (WHEN): Scoping Report.

    Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Ion 2005, 2005 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

64. Cyhoeddwyd

    Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease.

    Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Chwef 2005, Yn: Expert Review of Pharmacoeconomics and Outcomes Research. 5, 1, t. 29-38

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

65. Cyhoeddwyd

    Empirical analysis of the relationship between dose and duration of drug action

    Hughes, D. & Hughes, D. A., 1 Meh 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

66. Cyhoeddwyd

    Pharmacokinetics, patient compliance and pharmaeconomics

    Hughes, D. & Hughes, D. A., 1 Meh 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

67. Cyhoeddwyd

    Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: Pharmacoeconomic considerations.

    Hughes, D. & Hughes, D. A., 1 Gorff 2005, Yn: European Journal of Cancer. 41, 11, t. 1655

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

68. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Gorff 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

69. Cyhoeddwyd

    Drugs for exceptionally rare diseases: do they deserve special status for funding?

    Hughes, D., Tunnage, B. & Yeo, S. T., 1 Tach 2005, Yn: QJM - An International Journal of Medicine. 98, 11, t. 829-836

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

70. Cyhoeddwyd

    Incorporating measures of compliance and persistence in pharmacoeconomic evaluations

    Hughes, D., Hughes, D. A. & Cowell, W., 1 Tach 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

71. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Tach 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

72. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Tach 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

73. Cyhoeddwyd

    Trends and influences on use of antidiabetic drugs in England, 1992-2003.

    Walley, T., Hughes, D. & Kendall, H., 1 Tach 2005, Yn: Pharmacoepidemiology and Drug Safety. 14, 11, t. 769-773

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

74. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 11 Tach 2005, Yn: Value in Health. 8, 6, t. A192

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

75. 2006
76. Cyhoeddwyd

    Beyond registration: measuring the public health potential of new treatments for Malaria in Africa.

    Hughes, D., Lang, T., Hughes, D. A., Kanyok, T., Kengeya-Kayondo, J., Marsh, V., Haaland, A., Pirmohamed, M. & Winstanley, P., 1 Ion 2006, Yn: Lancet Infectious Diseases. 6, 1, t. 46-52

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

77. Cyhoeddwyd

    Health economic aspects of patient non-compliance

    Hughes, D., Hughes, D. A., Davies, M. (gol.) & Kermani, F. (gol.), 1 Ion 2006, Patient Compliance: Sweetening the Pill. 2006 gol. Gower Publishing, t. 23-40

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

78. Cyhoeddwyd

    Improving Outcomes for People with Brain and Other CNS Tumours: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Priedane, E., Hughes, D. A. & Edwards, R. T., 1 Ion 2006, 2006 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

79. Cyhoeddwyd

    Improving Outcomes for People with Sarcoma: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 1 Ion 2006, 2006 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

80. Cyhoeddwyd

    Less is more: Medicines that require less frequent administration improve adherence, but are they better?

    Hughes, D. & Hughes, D. A., 1 Ion 2006, Yn: Pharmacoeconomics. 24, 3, t. 211-213

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

81. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Ion 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

82. Cyhoeddwyd

    Rationing of drugs for rare diseases.

    Hughes, D. & Hughes, D. A., 1 Ion 2006, Yn: Pharmacoeconomics. 24, 4, t. 315-316

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

83. Cyhoeddwyd

    Improving Outcomes for People with Skin Tumours including Melanoma: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 21 Chwef 2006, Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

84. Cyhoeddwyd

    Eliciting patients' preferences using a discrete choice experiment questionnaire: the role played by qualitative data in questionnaire design

    Hughes, D., Longo, M., Hughes, D. A., Myles, S. & Lisles, C., 1 Maw 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

85. Cyhoeddwyd

    Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone.

    Simpson, J. A., Hughes, D., Manyando, C., Bojang, K., Aarons, L., Winstanley, P., Edwards, G., Watkins, W. A. & Ward, S., 1 Maw 2006, Yn: British Journal of Clinical Pharmacology. 61, 3, t. 289-300

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

86. Cyhoeddwyd

    Health and economic outcomes: Why compliance matters

    Hughes, D. & Hughes, D. A., 1 Ebr 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

87. Cyhoeddwyd

    Physchiatrist prescribing preferences and attitudes toward promotion

    Hughes, D., Menkes, D., Davies, R. & Hughes, D. A., 1 Ebr 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

88. Cyhoeddwyd

    Rationing of drugs for rare diseases

    Hughes, D. & Hughes, D. A., 1 Ebr 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

89. Cyhoeddwyd

    Back to basics: what is the relationship between dose and duration of drug action?

    Hughes, D. & Hughes, D. A., 1 Mai 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

90. Cyhoeddwyd

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments

    Hughes, D. & Hughes, D. A., 1 Mai 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

91. Cyhoeddwyd

    Orphan drugs revisited: author's response.

    Hughes, D. & Hughes, D. A., 1 Mai 2006, Yn: Quarterly Journal of Medicine. 99, 5, t. 350-351

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

92. Cyhoeddwyd

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment

    Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Meh 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

93. Cyhoeddwyd

    Prescription fee exemption research study

    Hughes, D., Myles, S., Hughes, D. A., Routledge, P. & Wales, D. F., 1 Meh 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

94. Cyhoeddwyd

    Clinical and econnomic importance of completion of therapy in the treatment of LRTIs

    Hughes, D. & Hughes, D. A., 1 Medi 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

95. Cyhoeddwyd

    Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?

    Hughes, D. & Hughes, D. A., 1 Tach 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

96. 2007
97. Cyhoeddwyd

    AWMSG criteria for appraising new medicines.

    Hughes, D. & Hughes, D. A., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

98. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A109

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

99. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

100. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

101. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Co-careldopa intestinal gel (Duodopa).

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

102. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Darunavir (Prezista)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

103. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

104. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Lymphoid blast CML and PH+ ALL.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

105. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Dexrazoxane (Savene)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

106. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

107. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Idursulfase (Elaprase)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

108. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

109. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Tipranavir (Aptivus).

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

110. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Assessment Report – Agalsidase alfa (Replagal)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

111. Cyhoeddwyd

     Assessing the association between compliance and therapeutic failure for antiretroviral drugs in HIV positive patients

     Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A171

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

112. Cyhoeddwyd

     Biological agents for the management of Crohn's disease in adults: A systematic review, meta-analysis and multiples treatment comparison

     Hughes, D., Hughes, D. A., Kikuchi, T. & Bodger, K., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A147

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

113. Cyhoeddwyd

     Factors influencing user choices to visit either general practitioners or community pharmacists for minor ailments – a discrete choice experiment

     Hughes, D., Hughes, D. A., Myles, S., Longo, M., Lisles, C. & Hood, K., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A23

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

114. Cyhoeddwyd

     Feasibility, validity, and reliability of the Welsh version of the EQ-5D health status questionnaire

     Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A189

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

115. Cyhoeddwyd

     Follow-up of cancer patients in primary care versus secondary care: systematic review.

     Hughes, D., Lewis, R., Neal, R., Williams, N., France, B., Wilkinson, C., Hendry, M., Russell, D., Hughes, D. A., Russell, I. T., Stuart, N. S. & Weller, D., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

116. Cyhoeddwyd

     Policy on ultra-orphan drugs.

     Hughes, D. & Hughes, D. A., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

117. Cyhoeddwyd

     Public health interventions to promote mental well-being in people aged 65 and over: systematic review of effectiveness and cost-effectiveness.

     Hughes, D., Windle, G., Hughes, D. A., Linck, P., Morgan, R., Burholt, V., Edwards, R. T., Reeves, C., Yeo, S. T., Woods, R. T. & Russell, I. T., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

118. Cyhoeddwyd

     Warfarin pharmacogenetics: Economic considerations.

     Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Ion 2007, Yn: Pharmacoeconomics. 25, 11, t. 899-902

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

119. Cyhoeddwyd

     When drugs don't work - Economic assessment of enhancing compliance with interventions supported by electronic monitoring devices.

     Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Pharmacoeconomics. 25, 8, t. 621-635

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

120. Cyhoeddwyd

     Adverse drug reactions in economic evaluations

     Hughes, D. & Hughes, D. A., 1 Maw 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

121. Cyhoeddwyd

     Assessing the association between compliance and therapeutic failure for antiretroviral drugs in HIV positive patients

     Hughes, D., 1 Maw 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

122. Cyhoeddwyd

     Economic evaluation of steroid injections (methylprednisolone) in the treatment of Morton's neuroma: patient-blind randomised trial

     Hughes, D., Thomson, C., Beggs, I., Martin, D., McCaldin, D., Russell, D., Edwards, R. T., Hughes, D. A., Yeo, S. T., Russell, I. T. & Gibson, T. N., 1 Maw 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

123. Cyhoeddwyd

     Falls and hip-fractures: A cost-effectiveness analysis of risk assessment and interventions for community-dwelling older people

     Hughes, D., Gwynne, D., Hughes, D. A. & Edwards, R. T., 1 Maw 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

124. Cyhoeddwyd

     Feasibility, validity and reliability of the Welsh EQ-5D health status questionnaire

     Hughes, D., 1 Maw 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

125. Cyhoeddwyd

     Non-compliance with antibiotic therapy for acute community infections: A global survey.

     Hughes, D., Pechere, J. C., Hughes, D. A., Kardas, P. & Cornaglia, G., 1 Maw 2007, Yn: International Journal of Antimicrobial Agents. 29, 3, t. 245-253

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

126. Cyhoeddwyd

     Systematic review of follow-up of cancer in primary care verses secondary care: findings for breast and lung cancer

     Hughes, D., Lewis, R., Neal, R. D., France, B., Williams, N. H., Wilkinson, C., Russell, I. T., Russell, D., Hughes, D. A., Stuart, N. S. & Weller, D., 1 Maw 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

127. Cyhoeddwyd

     Parenting programme for parents of children at risk of developing conduct disorder: cost effectiveness analysis.

     Bywater, T. J., Hutchings, J. M., Hughes, D., Edwards, R. T., Ceilleachair, A., Bywater, T., Hughes, D. A. & Hutchings, J., 31 Maw 2007, Yn: British Medical Journal. 334, 7595, t. 682-685

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

128. Cyhoeddwyd

     Adverse drug reactions: analysis by regulatory authorities and by economists

     Hughes, D. & Hughes, D. A., 1 Ebr 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

129. Cyhoeddwyd

     A parenting programme for children at risk of developing conduct disorder: A cost-effectiveness analysis

     Hughes, D., Edwards, R. T., Ceilleachair, A., Bywater, T., Hughes, D. A. & Hutchings, J., 1 Mai 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

130. Cyhoeddwyd

     Assessing the association between compliance and therapeutic failure for antiretroviral drugs in HIV positive patients

     Hughes, D. & Hughes, D. A., 1 Mai 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

131. Cyhoeddwyd

     Biological agents for the management of Crohn's disease in adults: a systematic review, meta-analysis and multiple treatment comparison

     Hughes, D., Hughes, D. A., Kikuchi, T. & Bodger, K., 1 Mai 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

132. Cyhoeddwyd

     Factors influencing user choices to visit either general practitioners or community pharmacists for minor ailments – a discrete choice experiment

     Hughes, D., Hughes, D. A., Myles, S., Longo, M., Lisles, C. & Hood, K., 1 Mai 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

133. Cyhoeddwyd

     Feasibility, validity and reliability of the Welsh EQ-5D health status questionnaire

     Hughes, D. & Hughes, D. A., 1 Mai 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

134. Cyhoeddwyd

     Quantitative risk-benefit analysis

     Hughes, D. & Hughes, D. A., 1 Mai 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

135. Cyhoeddwyd

     What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?

     Hughes, D., Hughes, D. A., LaFleur.*, N. V., Salas, M. & Shinogle, J., 1 Mai 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

136. Cyhoeddwyd

     Adherence with HAART: pharmacoeconomic considerations

     Hughes, D. & Hughes, D. A., 1 Meh 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

137. Cyhoeddwyd

     Adverse drug reactions in economic evaluations

     Hughes, D. & Hughes, D. A., 1 Gorff 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

138. Cyhoeddwyd

     A prototype agent-based model of antimalarial drug compliance

     Hughes, D., McKean, J., Rahlf, S., Shorter, H., Barnish, G., Paton, R., McBurney, P., Hughes, D. A. & Hastings, I., 1 Awst 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

139. Cyhoeddwyd

     Cost of non-compliance and non-persistence with medications for diabetes mellitus

     Hughes, D., Salas, M., Hughes, D. A., Lebmeier, M. & Vardeva, K., 1 Awst 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

140. Cyhoeddwyd

     Current assessment of risk-benefit by regulators: Is it time to introduce decision analyses?

     Hughes, D., Hughes, D. A., Pirmohamed, M. & Bayoumi, A., 1 Awst 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

141. Cyhoeddwyd

     Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?

     Hughes, D., Hughes, D. A., Bayoumi, A. M. & Pirmohamed, M., 1 Awst 2007, Yn: Clinical Pharmacology and Therapeutics. 82, 2, t. 123-127

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

142. Cyhoeddwyd

     Impact of the abolition of prescription charges in Wales: a multi-level modelling approach with application to time series dispensed rate data

     Hughes, D., Alam, F., Myles, S., Hughes, D. A., Dunstan, F., Routledge, P. & Cohen, D., 1 Medi 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

143. Cyhoeddwyd

     Feasibility, validity and reliability of the Welsh version of the EQ-5D health status questionnaire.

     Hughes, D. & Hughes, D. A., 1 Hyd 2007, Yn: Quality of Life Research. 16, 8, t. 1419-1423

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

144. Cyhoeddwyd

     Interventions that enhance medication compliance and persistence: Theoretical grounding, and economic assessment

     Hughes, D., Hughes, D. A., Gwadry Sridhar, F., Elliott, R. & Cowell, W., 1 Hyd 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

145. Cyhoeddwyd

     Pharmacoeconomic evaluations in Ireland, Scotland and Wales: A Celtic perspective on pharmaceutical assessment

     Hughes, D., Hughes, D. A., Drummond, M., Tolley, K. & Ryan, M., 1 Hyd 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

146. Cyhoeddwyd

     The assessment, determinants & economics of medication compliance & persistence

     Hughes, D., Hughes, D. A., Gwadry Sridhar, F. & Elliott, R., 1 Hyd 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

147. Cyhoeddwyd

     Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations.

     Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Tach 2007, Yn: Value in Health. 10, 6, t. 498-509

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

148. Cyhoeddwyd

     Orphan drug treatments: economic considerations

     Hughes, D. & Hughes, D. A., 1 Tach 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

149. Cyhoeddwyd

     Population pharmacokinetics of warfarin: Intermin analysis of the Liverpool pharmacogenetic prospective cohort study

     Hughes, D., Matthews, I., Aarons, L., Al-Zubiedi, S., Hatch, E., Lane, S., Williamson, P., Kamali, F., Hughes, D. A. & Pirmohamed, M., 1 Tach 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

150. Cyhoeddwyd

     The effect of compliance upon clinical effectiveness of chlorproguanil-dapsone (CD) and artemether-lumefantrine (AL) when compared to sulfadoxine-pyrimethamine (SP) for the treatment of uncomplicated falcipaum malaria in Malawi - a randomised controlled trial

     Hughes, D., Bell, D. J., Wootton, D., Mukaka, M., Montgomery, J., Kayange, N., Chimpeni, P., Zijlstra, E., Hughes D.A., N. V., Molyneux M.E.*, N. V., Ward, S. A., Winstanley, P. A. & Lalloo, D. G., 1 Tach 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

151. Cyhoeddwyd

     Folate Augmentation of Treatment – Evaluation for Depression (FolATED): protocol of a randomised controlled trial.

     Russell, I. T., Slegg, G. P., Roberts, S. H., Bedson, E., Hughes, D., Lloyd, K., Moat, S., Pirmohamed, M., Slegg, G., Tranter, R., Whitaker, R., Wilkinson, C. & Russell, I., 15 Tach 2007, Yn: BMC Psychiatry. 7, 1, t. 65

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

152. Cyhoeddwyd

     A Global Survey of Antibiotic Leftovers in the Outpatient Setting.

     Hughes, D., Kardas, P., Pechere, J. C., Hughes, D. A. & Cornaglia, G., 1 Rhag 2007, Yn: International Journal of Antimicrobial Agents. 30, 6, t. 530-536

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

153. Cyhoeddwyd

     Public meetings of the NICE appraisals committee

     Hughes, D. & Hughes, D. A., 1 Rhag 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

154. Cyhoeddwyd

     The pharmacokinetic profile of Warfarn: a systematic review

     Hughes, D., Al-Zubiedi S.*, N. V., Hughes D.A., N. V. & Pirmohamed, M., 1 Rhag 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

155. 2008
156. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

157. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

158. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

159. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

160. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

161. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

162. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

163. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

164. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

165. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

166. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

167. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

168. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Pegfilgrastim (Neulasta) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

169. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

170. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

171. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

172. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

173. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Teriparatide (Forsteo) for the treatment of osteoporosis in men at increased risk of fracture.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

174. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

175. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Trabectedin (Yondelis) for advanced soft tissue sarcoma.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

176. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Ziconotide (Prialt) for the intrathecal treatment of severe, chronic pain.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

177. Cyhoeddwyd

     Charitable contributions to funding cancer services for children and young people in England and Wales

     Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Ion 2008, Yn: Journal of Child Health Care. 12, 2, t. 156-168

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

178. Cyhoeddwyd

     Chiral chromatography: Costs of chiral switching.

     Hughes, D. & Hughes, D. A., 1 Ion 2008, Yn: Pharmaceutical Journal. 281, t. 213

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

179. Cyhoeddwyd

     Cost-effectiveness considerations in pharmacogenetics.

     Hughes, D. & Hughes, D. A., 1 Ion 2008.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

180. Cyhoeddwyd

     Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.

     Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

181. Cyhoeddwyd

     Effects of the abolition of prescription charges in Wales: a preliminary analysis.

     Hughes, D., Cohen, D., Alam, M. F., Hughes, D. A., Dunstan, F. & Routledge, P., 1 Ion 2008, Yn: International Journal of Pharmacy Practice. 16, Supplement 1, t. A39

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

182. Cyhoeddwyd

     Integrating compliance and persistence in health economics models

     Hughes, D. & Hughes, D. A., 1 Ion 2008.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

183. Cyhoeddwyd

     Investigating factors influencing user choices to visit either general practioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment.

     Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

184. Cyhoeddwyd

     Public health interventions to promote well-being in people aged 65 and over: systematic review of effectiveness and cost-effectiveness.

     Hughes, D., Linck, P. G., Windle, G., Hughes, D. A., Linck, P., Russell, I. T., Morgan, R., Woods, R. T., Burholt, V., Edwards, R. T., Reeves, C. & Yeo, S. T., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

185. Cyhoeddwyd

     Public health interventions to promote well-being in people aged 65 and over: systematic review of effectiveness and cost-effectiveness: Evidence Tables.

     Hughes, D., Linck, P. G., Windle, G., Linck, P., Morgan, R., Hughes, D. A., Burholt, V., Reeves, C., Yeo, S. T., Woods, R. T., Edwards, R. T. & Russell, I. T., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

186. Cyhoeddwyd

     Understanding medication compliance and persistence from an economics perspective

     Hughes, D., Elliot, R. A., Shinogle, J. A., Peele, P., Bhosle, M. & Hughes, D. A., 1 Ion 2008, Yn: Value in Health. 11, 4, t. 600-610

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

187. Cyhoeddwyd

     Economic considerations for market access of new health technologies: A case study of pharmacogenetic testing

     Hughes, D. & Hughes, D. A., 1 Chwef 2008.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

188. Cyhoeddwyd

     From efficacy to cost-effectiveness: Impact of patient compliance

     Hughes, D. & Hughes, D. A., 1 Chwef 2008.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

189. Cyhoeddwyd

     Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments – piloting a discrete choice experiment

     Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Maw 2008

     Allbwn ymchwil: Ffurf annhestunol › Safe Gwe / Cyhoeddiad Gwe

190. Cyhoeddwyd

     Statistical comments are unfounded.

     Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Maw 2008, Yn: Value in Health. 11, 2, t. 346

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

191. Cyhoeddwyd

     The cost-effectiveness of biological therapies for Crohn's disease: Markov cohort analyses incorporating UK patient-level cost data

     Hughes, D., Bodger, K., Kikuchi, T. & Hughes, D. A., 1 Maw 2008.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

192. Cyhoeddwyd

     Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

     Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ebr 2008.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

193. Cyhoeddwyd

     Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

     Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ebr 2008.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

194. Cyhoeddwyd

     Effects of the abolition of prescription charges in Wales: A preliminary analysis

     Hughes, D., Hughes, D. A., Alam, F., Cohen, D., Dunstan, F. & Routledge, P., 1 Ebr 2008.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

195. Cyhoeddwyd

     Costs of non-compliance to antipsychotic medications among patients with schizophrenia.

     Hughes, D., Hughes, D. A., Salas, M., Zuluaga, A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Mai 2008.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

196. Cyhoeddwyd

     The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data

     Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Mai 2008.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

197. Cyhoeddwyd

     Economic considerations for pharmacogenetic testing

     Hughes, D. & Hughes, D. A., 1 Meh 2008.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

198. Cyhoeddwyd

     Medicines concordance and game theory.

     Hughes, D. & Hughes, D. A., 1 Hyd 2008, Yn: British Journal of Clinical Pharmacology. 66, 4, t. 577

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

199. Cyhoeddwyd

     Impact of the abolition of the prescription charge in Wales

     Hughes, D. & Hughes, D. A., 1 Tach 2008.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

200. Cyhoeddwyd

     Methodological Issues in the literature on costs of non-compliance in chronic diseases.

     Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Tach 2008, Yn: Value in Health. 11, 6, t. A571-A572

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

201. Cyhoeddwyd

     Methodological issues in the literature on costs of non-compliance in chronic diseases

     Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeie, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Tach 2008.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

202. Cyhoeddwyd

     The all wales medicines strategy group: assessments and appraisals

     Hughes, D. & Hughes, D. A., 1 Tach 2008.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

203. Cyhoeddwyd

     Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens

     Hughes, D. & Hughes, D. A., 1 Rhag 2008, Yn: British Journal of Clinical Pharmacology. 65, 6, t. 871-878

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

204. 2009
205. Cyhoeddwyd

     A systematic review and empirical analysis of the relation between dose and duration of drug action.

     Hughes, D., Hughes, D. A. & Aronson, J. K., 1 Ion 2009, t. TP40.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

206. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

207. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

208. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

209. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Tacrolimus (Advagraf) for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

210. Cyhoeddwyd

     Assessment, Determinants & Economics of Medication Compliance & Persistence Forum.

     Hughes, D., Hughes, D. A., Gwadry-Sridhar, F. & Manias, E., 1 Ion 2009.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

211. Cyhoeddwyd

     Biosimilars: Evidential standards for health technology assessment.

     Hughes, D. & Hughes, D. A., 1 Ion 2009.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

212. Cyhoeddwyd

     Biosimilars: Evidential standards for health technology assessment.

     Hughes, D. & Hughes, D. A., 1 Ion 2009.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

213. Cyhoeddwyd

     Comparisons between the medication possession ratio (MPR) and gaps measures of medication compliance: are we selling ourselves short by relying on the MPR?

     Hughes, D., Nichol, M., Manias, E., Hughes, D. A. & Schabert, V. F., 1 Ion 2009.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

214. Cyhoeddwyd

     Drug evaluation and pharmocoeconomics.

     Hughes, D., Krska, J., Hughes, D. A., Winfield, A. J. (gol.), Rees, J. A. (gol.) & Smith, I. (gol.), 1 Ion 2009, Pharmaceutical Practice: 4th Edition.. 2009 gol. Churchill Livingstone, t. 185-198

     Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

215. Cyhoeddwyd

     Economic evaluation of infliximab and adalimumab for Crohn's disease.

     Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ion 2009.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

216. Cyhoeddwyd

     Engaging with the MRC Methodology Hubs – NWHTMR.

     Hughes, D. & Hughes, D. A., 1 Ion 2009.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

217. Cyhoeddwyd

     Impact of pharmacogenetics on the costs of managing adverse events with warfarin: A prospective analysis.

     Hughes, D., Hughes, D. A., Al-Zubiedi, S., Hanson, A., Jorgensen, A. & Pirmohamed, M., 1 Ion 2009.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

218. Cyhoeddwyd

     Impact of the abolition of the prescription charge in Wales.

     Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

219. Cyhoeddwyd

     Impact of the abolition of the prescription charge in Wales.

     Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

220. Cyhoeddwyd

     Impact of the abolition of the prescription charge in Wales.

     Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009, t. O41.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

221. Cyhoeddwyd

     The economics of evergreening.

     Hughes, D. & Hughes, D. A., 1 Ion 2009.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

222. Cyhoeddwyd

     A Framework for Planning and Critiquing Medication Compliance and Persistence Research Using Prospective Study Designs.

     Hughes, D., Gwadry-Sridhar, F. H., Manias, E., Zhang, Y., Roy, A., Yu-Isenberg, K., Hughes, D. A. & Nichol, M. B., 1 Chwef 2009, Yn: Clinical Therapeutics. 31, 2, t. 421-435

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

223. Cyhoeddwyd

     Nurse-led vs. conventional physician-led follow-up for patients with cancer: systematic review

     Lewis, R., Neal, R. D., Williams, N. H., France, B., Wilkinson, C. E., Hendry, M., Russell, D., Russell, I., Hughes, D., Stuart, N. S. & Weller, D., 1 Ebr 2009, Yn: Journal of Advanced Nursing. 65, 4, t. 706-723

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

224. Cyhoeddwyd

     Estimating Drug Costs in Economic Evaluations in Ireland and the UK: An Analysis of Practice and Research Recommendations.

     Hughes, D., Hughes, D. A., Tilson, L. & Drummond, M. F., 1 Mai 2009, Yn: Pharmacoeconomics. 27, 8, t. 635-643

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

225. Cyhoeddwyd

     Patients' and healthcare professionals' views of cancer follow-up: systematic review

     Lewis, R., Neal, R. D., Hendry, M., France, B., Williams, N. H., Russell, D., Hughes, D. A., Russell, I., Stuart, N. S. A., Weller, D. & Wilkinson, C., Gorff 2009, Yn: British Journal of General Practice. 59, 564, t. e248-e259

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

226. Cyhoeddwyd

     Follow-up of cancer in primary care versus secondary care: systematic review

     Lewis, R. A., Neal, R. D., Williams, N. H., France, B., Hendry, M., Russell, D., Hughes, D. A., Russell, I., Stuart, N. S. A., Weller, D. & Wilkinson, C., 1 Gorff 2009, Yn: British Journal of General Practice. 59, 564, t. e234-e247

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

227. Cyhoeddwyd

     Cost and clinical consequence of antibiotic non-adherence in acute exacerbations of chronic bronchitis.

     Sorensen, S. V., Baker, T., Fleurence, R., Dixon, J., Roberts, C., Haider, S. & Hughes, D., 1 Awst 2009, Yn: International Journal of Tuberculosis and Lung Disease. 13, 8, t. 945-954

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

228. Cyhoeddwyd

     Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data.

     Hughes, D., Bodger, K., Kikuchi, T. & Hughes, D. A., 1 Awst 2009, Yn: Alimentary Pharmacology and Therapeutics. 30, 3, t. 265-274

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

229. Cyhoeddwyd

     Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi.

     Hughes, D., Bell, D. J., Wootton, D., Mukaka, M., Montgomery, J., Kayange, N., Chimpeni, P., Hughes, D. A., Molyneux, M. E., Ward, S. A., Winstanley, P. A. & Lalloo, D. G., 26 Awst 2009, Yn: Malaria Journal. 8, t. 204

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

230. Cyhoeddwyd

     Costs of Medication Nonadherence in Patients with Diabetes Mellitus: A Systematic Review and Critical Analysis of the Literature.

     Hughes, D., Salas, M., Hughes, D. A., Zuluaga, A., Vardeva, K. & Lebmeier, M., 1 Medi 2009, Yn: Value in Health. 12, 6, t. 915-922

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

231. Cyhoeddwyd

     Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.

     Hughes, D., Jorgensen, A. L., Al-Zubiedi, S., Zhang, J. E., Keniry, A., Hanson, A., Hughes, D. A., Van Eker, D., Stevens, L., Hawkins, K., Toh, C. H., Kamali, F., Daly, A. K., Fitzmaurice, D., Coffey, A., Williamson, P. R., Park, B. K., Deloukas, P. & Pirmohamed, M., 1 Hyd 2009, Yn: Pharmacogenetics and Genomics. 19, 10, t. 800-812

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

232. Cyhoeddwyd

     Pharmacoeconomics: principles and relevance to the activities of drug and therapeutics committees.

     Hughes, D., Hughes, D. A. & Reynolds, D. J., 1 Hyd 2009, Yn: Clinical Medicine. 9, 5, t. 490-492

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

233. 2010
234. Cyhoeddwyd

     Enhancing methodical approaches for studying bilingualism in healthcare communication: report of a trial feasibility study.

     Roberts, G. W., Hughes, D., Roberts, G., Owen, H., Hughes, L., Whitaker, R., Deuchar, M., Hughes, D. A., Llewelyn, S., John, S., Irvine, F., Owen, B. & Rowlands, A., 1 Ion 2010.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

235. Cyhoeddwyd

     NICE and new: appraising innovation.

     Hughes, D., Ferner, R. E., Hughes, D. A. & Aronson, J. K., 5 Ion 2010, Yn: British Medical Journal. 340, t. b5493

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

236. Cyhoeddwyd

     New drugs for old: disinvestment and NICE.

     Hughes, D., Hughes, D. A. & Ferner, R. E., 25 Chwef 2010, Yn: British Medical Journal. 340, t. c572

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

237. Cyhoeddwyd

     Biosimilars: Evidential standards for health technology assessment.

     Hughes, D. & Hughes, D. A., 1 Maw 2010, Yn: Clinical Pharmacology and Therapeutics. 87, 3, t. 257-261

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

238. Cyhoeddwyd

     A systematic review of cost–effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives

     Hughes, D., Verhoef, T. I., Redekop, W. K., Darba, J., Geitona, M., Hughes, D. A., Siebert, U., de Boer, A., Maitland-van der Zee, A. H., Barallon, R., Briz, M., Daly, A., Haschke-Becher, E., Kamali, F., Kirchheiner, J., Manolopoulos, V. G., Pirmohamed, M., Rosendaal, F. R., van Schie, R. M. & Wadelius, M., 1 Gorff 2010, Yn: Pharmacogenomics. 11, 7, t. 989-1002

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

239. Cyhoeddwyd

     Abolition of prescription copayments in Wales: an observational study on dispensing rates.

     Hughes, D., Cohen, D., Alam, M. F., Dunstan, F. D., Myles, S., Hughes, D. A. & Routledge, P. A., 1 Awst 2010, Yn: Value in Health. 13, 5, t. 675-680

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

240. Cyhoeddwyd

     Is exercise effective in promoting mental well-being in older age? A systematic review.

     Hughes, D., Linck, P. G., Windle, G., Hughes, D. A., Linck, P., Russell, I. T. & Woods, R. T., 1 Awst 2010, Yn: Aging and Mental Health. 14, 6, t. 652-669

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

241. Cyhoeddwyd

     From NCE to NICE: the role of pharmacoeconomics

     Hughes, D. & Hughes, D. A., 1 Medi 2010, Yn: British Journal of Clinical Pharmacology. 70, 3, t. 317-319

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

242. Cyhoeddwyd

     Generic and therapeutic substitutions in the UK: are they a good thing?

     Hughes, D., Duerden, M. G. & Hughes, D. A., 1 Medi 2010, Yn: British Journal of Clinical Pharmacology. 70, 3, t. 335-341

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

243. Cyhoeddwyd

     The problem of orphan drugs

     Hughes, D., Ferner, R. E. & Hughes, D. A., 16 Tach 2010, Yn: British Medical Journal. 341, t. 335-341

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

244. Cyhoeddwyd

     Abolition of prescription charges in Wales: the impact on medicines use in those who used to pay

     Hughes, D., Groves, S., Cohen, D., Alam, M. F., Dunstan, F. D., Routledge, P. A., Hughes, D. A. & Myles, S., 1 Rhag 2010, Yn: International Journal of Pharmacy Practice. 18, 6, t. 332-340

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

245. Cyhoeddwyd

     Methods for the collection of resource use data within clinical trials: A systematic review of studies funded by the UK Health Technology Assessment Program

     Ridyard, C. H. & Hughes, D., 1 Rhag 2010, Yn: Value in Health. 13, 8, t. 867-872

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

246. 2011
247. Cyhoeddwyd

     Involving colleagues can be challenging

     Fargher, E. & Hughes, D., 2 Ebr 2011, Yn: Pharmaceutical Journal. 286, t. 404

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Llythyr › adolygiad gan gymheiriaid

248. Cyhoeddwyd

     Value-Based Pricing: Incentive for Innovation or Zero Net Benefit?

     Hughes, D. & Hughes, D. A., 1 Medi 2011, Yn: Pharmacoeconomics. 29, 9, t. 731-735

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

249. Cyhoeddwyd

     Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

     Hughes, D., Pink, J., Lane, S., Pirmohamed, M. & Hughes D.A., N. V., 31 Hyd 2011, Yn: British Medical Journal. 343, t. 1-14

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

250. Cyhoeddwyd

     HTAs and rare diseases: How to assess their cost-effectiveness

     Hughes, D., Phillips, C. J. & Hughes, D. A., 1 Tach 2011, Yn: Pharmaceuticals Policy and Law. 13, 3-4, t. 161-165

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

251. 2012
252. Cyhoeddwyd

     The Population Pharmacokinetics of R and S-Warfarin: Effect of Genetic and Clinical Factors

     Hughes, D., Lane, S., Al-Zubiedi, S., Hatch, E., Matthews, I., Jorgensen, A. L., Deloukas, P., Daly, A. K., Aarons, L., Ogungbenro, K., Kamali, F., Hughes, D. A. & Pirmohamed, M., 1 Ion 2012, Yn: British Journal of Clinical Pharmacology. 73, 1, t. 66-76

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

253. Cyhoeddwyd

     Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals: Pharmacokinetic/Pharmacodynamic/Pharmacoeconomic Analysis of Rituximab for Follicular Lymphoma.

     Hughes, D., Pink, J., Lane, S. & Hughes, D. A., 19 Maw 2012, Yn: Pharmacoeconomics.

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

254. Cyhoeddwyd

     A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention

     Hughes, D., Guzauskas, G. F., Hughes, D. A., Bradley, S. M. & Veenstra, D. L., 28 Maw 2012, Yn: Clinical Pharmacology and Therapeutics.

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

255. Cyhoeddwyd

     Defining rewardable innovation in drug therapy

     Hughes, D., Aronson, J. K., Ferner, R. E. & Hughes, D. A., 1 Ebr 2012, Yn: Nature Reviews Drug Discovery. 11, t. 253-254

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

256. Cyhoeddwyd

     An explanatory randomised controlled trial of a nurse-led, consultation-based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetes

     Hughes, D., Farmer, A., Hardeman, W., Hughes, D. A., Prevost, A. T., Kim, Y., Craven, A., Oke, J., Boase, S., Selwood, M., Kellar, I., Graffy, J., Griffin, S., Sutton, S. & Kinmonth, A. L., 5 Ebr 2012, Yn: BMC Family Practice. 13, 30

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

257. Cyhoeddwyd

     A new taxonomy for describing and defining adherence to medications

     Holmes, E. A., Hughes, D., Morrison, V. L., Vrijens, B., De Geest, S., Hughes, D. A., Prezemyslaw, K., Demonceau, J., Ruppar, T., Dobbels, F., Fargher, E., Morrison, V., Lewek, P., Matyjaszczyk, M., Mshelia, C., Clyne, W., Aronson, J. K. & Urquhart, J., 1 Mai 2012, Yn: British Journal of Clinical Pharmacology. 73, 5, t. 691-705

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

258. Cyhoeddwyd

     The development of a QALY measure for epilepsy: NEWQOL-6D

     Hughes, D., Mulhern, B., Rowen, D., Jacoby, A., Marson, T., Snape, D., Hughes, D. A., Latimer, N., Baker, G. A. & Brazier, J. E., 1 Mai 2012, Yn: Epilepsy and Behavior. 24, 1, t. 36-43

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

259. Cyhoeddwyd

     An agenda for UK clinical pharmacology Pharmacoeconomics

     Hughes, D. & Hughes, D. A., 1 Meh 2012, Yn: British Journal of Clinical Pharmacology. 73, 6, t. 968-972

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

260. Cyhoeddwyd

     Development of a Database of Instruments for Resource-Use Measurement: Purpose, Feasibility, and Design

     DIRUM Team, 1 Gorff 2012, Yn: Value in Health. 15, 5, t. 650-655

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

261. Cyhoeddwyd

     Cost–effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs

     Hughes, D., Verhof, T. I., Redekop, W. K., van Schie, R. M., Bayat, S., Daly, A. K., Geitona, M., Haschke-Becher, E., Hughes, D. A., Kamali, F., Levin, L. A., Manolopoulos, V. G., Pirmohamed, M., Siebert, U., Stingl, J. C., Wadelius, M., de Boer, A. & Maitland-van der Zee, A. H., 1 Medi 2012, Yn: Pharmacogenomics. 13, 12, t. 1405-1417

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

262. Cyhoeddwyd

     Reimbursement Decisions of the All Wales Medicines Strategy Group

     Hughes, D., Linley, W. G. & Hughes, D. A., 1 Medi 2012, Yn: PharmoEconomics. 30, 9, t. 779-794

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

263. Cyhoeddwyd

     Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

     Hughes, D., Faulkner, E., Annemans, L., Garrison, L., Helfand, M., Holtorf, A. P., Hornberger, J., Hughes, D. A., Li, T., Malone, D., Payne, K., Siebert, U., Towse, A., Veenstra, D. & Watkins, J., 1 Rhag 2012, Yn: Value in Health. 15, 8, t. 1162-1171

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid